Share This Article:

Prevalence of metabolic syndrome in type 2 diabetic patients: A comparative study using WHO, NCEP ATP III, IDF and Harmonized definitions

Abstract Full-Text HTML XML Download Download as PDF (Size:238KB) PP. 1689-1696
DOI: 10.4236/health.2013.510227    4,066 Downloads   6,158 Views   Citations

ABSTRACT

To determine the prevalence of metabolic syndrome (MetS) in Malaysian type 2 diabetic patients using WHO, NCEP ATP III, IDF and the new Harmonized definitions, and the concordance between these definitions. This study involved 313 patients diagnosed with type 2 diabetes mellitus (T2DM) at two Malaysian tertiary hospitals. Socio-demographic data were assessed using a pre-tested interviewer-administered structured questionnaire. Anthropometric measurements were carried out according to standard protocols. Clinical and laboratory characteristics were examined. Kappa (k) statistics were used for the agreement between the four MetS definitions. The overall prevalence rates of MetS (95% CI) were 95.8% (93.6-98.1), 96.1% (94.0-98.3), 84.8% (80.8-88.9) and 97.7% (96.1-99.4) according to the WHO, NCEP ATP III, IDF and the Harmonized definitions, respectively. The Kappa statistics demonstrated a slight to substantial agreement between the definitions (k = 0.179-0.875, p < 0.001), where the WHO criteria revealed the highest concordance with the NCEP ATP III definition (k = 0.875, p < 0.001). The WHO against NCEP ATP III criteria evinced the highest sensitivity (99.66%) whereas Harmonized criteria against all the other three definitions showed the highest specificity (100%) in identifying MetS. In conclusion, the new Harmonized criteria established the highest prevalence of MetS among the four definitions applied. There was a very good concordance between the WHO and NCEP ATP III criteria. The extremely high prevalence of MetS observed in type 2 diabetic patients indicates an impending pandemic of CVD risk in Malaysia. Aggressive treatment of MetS components is required to reduce cardiovascular risk in T2DM.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Tan, M. C. , Ng, O. C. , Wong, T. W. , Joseph, A. , Chan, Y. M. and Hejar, A. R. (2013) Prevalence of metabolic syndrome in type 2 diabetic patients: A comparative study using WHO, NCEP ATP III, IDF and Harmonized definitions. Health, 5, 1689-1696. doi: 10.4236/health.2013.510227.

References

[1] American Heart Association (2009) Heart disease and stroke statistics: 2009 update. American Heart Association, Dallas.
[2] Alberti, K.G., Zimmet, P. and Shaw, J. (2005) The metabolic syndrome: A new worldwide definition. Lancet, 366, 1059-1062.
http://dx.doi.org/10.1016/S0140-6736(05)66835-3
[3] NCEP Expert Panel (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA, 285, 2486-2497.
http://dx.doi.org/10.1001/jama.285.19.2486
[4] IDF (2006) The IDF consensus worldwide definition of the metabolic syndrome.
http://www.idf.org/metabolic_syndrome
[5] WHO (1999) Definitions, diagnosis and classification of diabetes mellitus and its complication. Report of a WHO consultation. Department of Non-Communicate Disease Surveillance, Geneva.
[6] American Heart Association (2012) Heart disease and stroke statistics-2012 update: A report from the American Heart Association. Circulation, 125, e2-e220.
[7] Alberti, K.G., Eckel, R.H., Grundy, S.M., Zimmet, P.Z., Cleeman, J.I., Donato, K.A., et al. (2009) Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 120, 1640-1645.
http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192644
[8] Afsana, F., Latif, Z.A., Khan, S.J. and Talukder, S.K. (2010) Metabolic syndrome and cardiovascular risk in diabetic subjects. CVD Prevention and Control, 5, 59-62.
http://dx.doi.org/10.1016/j.cvdpc.2010.05.001
[9] Kendall, D.M. and Harmel, A.P. (2002) The metabolic syndrome, type 2 diabetes, and cardiovascular disease: Understanding the role of insulin resistance. American Journal of Management Care, 8, S635-S653.
[10] Bonora, E., Targher, G., Formentini, G., Calcaterra, F., Lombardi, S., Marini, F., et al. (2003) The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabetic Medicine, 21, 52-58.
http://dx.doi.org/10.1046/j.1464-5491.2003.01068.x
[11] Nakanishi, N., Takatorige, T., Fukuda, H., Shirai, K., Li, W., Okamotoa, M., et al. (2004) Components of the metabolic syndrome as predictors of cardiovascular disease and type 2 diabetes in middle-aged Japanese men. Diabetes Research and Clinical Practice, 64, 59-70.
http://dx.doi.org/10.1016/j.diabres.2003.10.001
[12] Guzder, R.N., Gatling, W., Mullee, M.A. and Byrne, C.D. (2006) Impact of metabolic syndrome criteria on cardiovascular disease risk in people with diagnosed type 2 diabetes. Diabetologia, 49, 49-55.
http://dx.doi.org/10.1007/s00125-005-0063-9
[13] Kim, W.Y., Kim, J.E., Choi, Y.J. and Huh, K.B. (2008) Nutritional risk and metabolic syndrome in Korean type 2 diabetes mellitus. Asia Pacific Journal of Clinical Nutrition, 17, 47-51.
[14] AlSaraj, F., McDermott, J.H., Cawood, T., McAteer, S., Ali, M., Tormey, W., et al. (2009) Prevalence of the metabolic syndrome in patients with diabetes mellitus. Ireland Journal of Medical Sciences, 178, 309-313.
http://dx.doi.org/10.1007/s11845-009-0302-z
[15] Thorn, L.M., Forsblom, C., Fagerudd, J., Thomas, M.C., Pettersson-Fernholm, K., Saraheimo, M., et al. (2005) Metabolic syndrome in type 1. Diabetes, 28, 2019-2014.
[16] Eckel, R.H., Grundy, S.M. and Zimmet, P.Z. (2005) The metabolic syndrome. The Lancet, 365, 1415-1428.
http://dx.doi.org/10.1016/S0140-6736(05)66378-7
[17] Zimmet, P., Magliano, D., Matsuzawa, Y., Alberti, G. and Shaw, J. (2005) The metabolic syndrome: A global public health problem and a new definition. Journal of Atherosclerosis and thrombosis, 12, 295-300.
http://dx.doi.org/10.5551/jat.12.295
[18] Ford, E.S. (2005) Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care, 28, 2745-2749.
[19] Lien, L.F. and Guyton JR. (2008) Metabolic syndrome. Dermatologic Therapy, 21, 362-375.
http://dx.doi.org/10.1111/j.1529-8019.2008.00218.x
[20] Grundy, S.M., Cleeman, J.I., Daniels, S.R., Donato, K.A., Eckel, R.H., Franklin, B.A., et al. (2005) Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung and Blood Institute scientific statement. Circulation, 112, 2735-2752.
http://dx.doi.org/10.1161/CIRCULATIONAHA.105.169404
[21] Huang, P.L. (2009) A comprehensive definition for metabolic syndrome. Disease Models & Mechanisms, 2, 231-237. http://dx.doi.org/10.1242/dmm.001180
[22] MOH Malaysia (2011) Malaysian guideline for good clinical practice. 3rd Edition, MOH Malaysia, Putrajaya.
[23] WHO (1995) Physical Status: The use and interpretation of anthropometry. Report of a WHO Expert Committee. WHO Technical Report Series 854. WHO, Geneva.
[24] MOH Malaysia (2009) Clinical practice guidelines: Management of Type II Diabetes Mellitus. 4th Edition, MOH Malaysia, Putrajaya.
[25] Orna, J.A.G., Arnal, L.M.L., Herguedas, E.M., Julián, B.B. and Córdobaa, D.P.P. (2004) Metabolic syndrome as a cardiovascular risk factor in patients with type 2 diabetes. Revista Espanola de Cardiología, 57, 507-513.
[26] Lu, W., Resnick, H.E., Jablonski, K.A., Jones, K.L., Jain, A.K., Howard, W.J., et al. (2003) Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: The strong heart study. Diabetes Care, 26, 16-23.
http://dx.doi.org/10.2337/diacare.26.1.16
[27] Isomaa, B., Henricsson, M., Almgren, P., Tuomi, T., Taskinen, M.R. and Groop, L. (2001b) The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia, 44, 1148-1154.
http://dx.doi.org/10.1007/s001250100615
[28] Protopsaltis, I., Nikolopoulos, G., Dimoua, E., Brestas, P., Kokkoris, S., Korantzopoulos, P., et al. (2007) Metabolic syndrome and its components as predictors of all-cause mortality and coronary heart disease in type 2 diabetic patients. Atherosclerosis, 195, 189-194.
http://dx.doi.org/10.1016/j.atherosclerosis.2006.09.019
[29] Monami, M., Masotti, N.M.G. and Mannucci, E. (2007) IDF and ATP-III definitions of metabolic syndrome in the prediction of all-cause mortality in type 2 diabetic patients. Diabetes, Obesity and Metabolism, 9, 350-353.
http://dx.doi.org/10.1111/j.1463-1326.2006.00615.x
[30] Hanefeld, M., Koehler, C., Gallo, S., Benke, I. and Ott, P. (2007) Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: The Diabetes in Germany (DIG) study. Cardiovascular Diabetology, 6, 13.
http://dx.doi.org/10.1186/1475-2840-6-13
[31] Bruno, G., Merletti, F., Biggeri, A., Bargero, G., Ferrero, S., Runzo, C., et al. (2004) Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: The Casale Monferrato study. Diabetes Care, 27, 2689-2694.
http://dx.doi.org/10.2337/diacare.27.11.2689

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.